

A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors

Clinical summary

BGB-58067 is a new drug designed to target a protein called PRMT5. This protein is involved in many cell processes and can help cancer growth when it is overactive. High levels of PRMT5 are linked to poor outcomes in several types of cancer.

This study is looking at how safe BGB-58067 is, how it behaves in the body, and whether it shows early signs of working.

The drug will be tested:

on its own;

in combination with BG-89894; and

in combination with standard of care therapy.

The study is recruiting people with advanced solid cancers that cannot be removed with surgery, have spread, or are locally advanced, and have a tumour with MTAP deficiency.

Most participants will have had treatment before, and their cancer has come back or worsened, or there are no suitable standard treatment options available. Some groups in the study may include people who have not yet received treatment.

Conditions

This trial is treating patients with advanced, metastatic or inoperable (unresectable) solid cancers who have previously received treatment and whose tumours are MTAP deficient

Trial Acronym

Trial Identifiers

NCT06589596

BGB-58067-101; CTR20244451

2024-515307-19-00

Cancer

Adenoid cystic carcinoma, Adrenocortical carcinoma, Anus, Appendix, Astrocytoma, Basal cell carcinoma, Bile duct (Cholangiocarcinoma), Bladder, Bone, Brain, Brain stem, Breast, Cancer of Unknown Primary, Central Nervous System, Cervix, Chondrosarcoma, Colon, Colorectum (Bowel), Cutaneous Squamous Cell Carcinoma (CSCC), Endometrium, Ependymomas, Epithelial, Ewing's Sarcoma, Fallopian tube, Gallbladder, Gastrointestinal stromal tumors (GISTs), Gastro-oesophageal junction , Germ cell and sex cord stromal cell, Germ cell tumour, Glioblastoma (GBM) , Glioma, Head and neck, Kaposi Sarcoma, Kidney, Leiomyosarcoma, Liposarcoma, Liver, Lung, Medullablastoma, Melanoma (Ocular), Melanoma (Skin), Meningioma, Merkel cell, Mesothelioma, Neuroblastoma, Neuroendocrine tumours, Non-Small Cell Lung Cancer, Nose (nasopharynx), Oesophagus, Oral cavity, Oropharynx, Osteosarcoma, Ovary, Pancreas, Penis, Peritoneal, Prostate, Rectum, Renal cell carcinoma, Retinoblastoma, Rhabdomyosarcoma, Salivary glands, Sarcoma, Small bowel (small intestine) cancer, Small Cell Lung Cancer, Soft Tissue Sarcoma, Spinal Cord, Squamous cell carcinoma (Head and Neck), Squamous cell carcinoma (Skin), Stomach (Gastric), Stromal Sarcoma, Synovial Sarcoma, Testis, Throat (hypopharynx), Thyroid, Urinary tract, Urothelial, Uterus, Vagina, Voice box (larynx), Vulva, Wilm's tumour

Age: 18+

Phase: I

For full trial details, visit trials.cancervic.org.au/details/vctI_nct06589596